PULMONX CORP

NASDAQ: LUNG (Pulmonx Corporation)

Kemas kini terakhir: 36 minit lalu

2.74

0.05 (1.86%)

Penutupan Terdahulu 2.69
Jumlah Dagangan 503,210
Harga / Jualan (P/S) 1.32
Harga / Buku (P/B) 3.48
Julat 52 Minggu
1.13 (-58%) — 3.25 (18%)
Margin Keuntungan -65.27%
Margin Operasi (TTM) -64.61%
EPS Cair (TTM) -1.44
Pertumbuhan Hasil Suku Tahunan (YOY) 19.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 73.32%
Nisbah Semasa (MRQ) 4.97
Aliran Tunai Operasi (OCF TTM) -32.96 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -13.19 M
Pulangan Atas Aset (ROA TTM) -22.20%
Pulangan Atas Ekuiti (ROE TTM) -60.68%

AISkor Stockmoo

0.1
Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Tiada aliran jelas sepanjang tahun lalu. Agak di bawah paras tertinggi 52 minggu. info
Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini kebanyakannya positif. info
Sentimen Pegangan info NA
Institusi bersih +3.45% daripada saham dalam pemfailan 13F terkini: 45 pemegang menambah, 67 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -19.3% dari 31 Aug hingga 30 Oct 2026, 1 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Di atas garis aliran jangka sederhana. info
Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek meningkat. info
Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menaik. info
Skor Akhir 0.14
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Devices (US) Bercampur Bercampur
Medical Devices (Global) Bercampur Bercampur
Stok Pulmonx Corporation Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
LUNG - - - 3.48 0.1
SMLR 368 M - 7.48 - -0.4
BSGM 169 M - - 36.58 -0.1
IINN 19 M - - 13.64 -0.4
PTHL 15 M - - 2.19 0.0
RSLS 4 M - 0.019 30.42 -0.8

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Sektor Healthcare
Industri Medical Devices
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 4.40%
% Dimiliki oleh Institusi 90.83%

Pemilikan

Nama Tarikh Syer Dipegang
Primecap Management Co/Ca/ 30 Sep 2026 4,408,431
Soleus Capital Management, L.P. 30 Sep 2026 3,088,323
Almitas Capital Llc 30 Sep 2026 1,080,038
Parkman Healthcare Partners Llc 30 Sep 2026 853,986
Braidwell Lp 30 Sep 2026 752,541
D. E. Shaw & Co., Inc. 30 Sep 2026 740,868
Marshall Wace, Llp 30 Sep 2026 660,466
Acadian Asset Management Llc 30 Sep 2026 522,987

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 67.43%

Kedudukan Pemegang Saham
Bertambah 45 4,687,719
Berkurang 67 3,808,268
Baharu 17 1,217,235
Dijual habis 24 578,840

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 787,512 1.0
15 Oct 2026 698,644 2.5
30 Sep 2026 802,733 3.2
15 Sep 2026 847,842 2.5
31 Aug 2026 976,237 2.6
14 Aug 2026 1,066,574 1.2

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

2 Positif 0 Negatif 1 Neutral
Tarikh Jenis Butiran
18 Nov 2026 Yahoo Finance Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare…
17 Nov 2026 Yahoo Finance Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilationREDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in…
08 Nov 2026 Yahoo Finance Pulmonx: 3 Key Takeaways for Long-Term Investors
Gross margins above 75% and a narrowing path to cash flow breakeven give the turnaround real financial teeth.
30 Oct 2026 Yahoo Finance All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
28 Oct 2026 Yahoo Finance Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity…
27 Oct 2026 Yahoo Finance Pulmonx (LUNG) Q3 2026 Earnings Call Transcript
Revenue returned to growth while losses narrowed significantly on cost discipline.
27 Oct 2026 Yahoo Finance What Pulmonx (LUNG) Said on Its Q3 Earnings Call
Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market. Total worldwide revenue for the quarter ended Sept. 30 was $22…
27 Oct 2026 Yahoo Finance Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
27 Oct 2026 Yahoo Finance Pulmonx Reports Third Quarter 2026 Financial Results
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026. Recent Highlights…
13 Oct 2026 Yahoo Finance Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday…
03 Sep 2026 Yahoo Finance Pulmonx Shares Fall Following Recent Gains
Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2…
01 Sep 2026 Yahoo Finance Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025…
26 Aug 2026 Yahoo Finance Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Papar semua

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik.
Sokongan terdekat: 2.36 – 2.66 · paras kukuh · kerap diuji, mungkin pecah
Rintangan terdekat: 3.10 – 3.32 · paras kukuh

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda